Literature DB >> 21327565

New immunomodulatory drugs in myeloma.

Martha Q Lacy1.   

Abstract

Multiple myeloma (MM) is an incurable malignancy of plasma cells. The introduction of thalidomide was a milestone in the treatment of MM. Thalidomide analogues termed immunomodulatory drugs (IMiDs) have been developed that are more effective and have less toxicity than thalidomide. The role of lenalidomide in relapsed MM has been well defined. This review discusses the data regarding the upfront use of lenalidomide with dexamethasone or in multidrug combinations, as well as its potential role as maintenance therapy. It also reviews our experience with pomalidomide, a new IMid with remarkable activity in relapsed, refractory MM.

Entities:  

Mesh：

Substances：

Year:  2011        PMID： 21327565     DOI： 10.1007/s11899-011-0077-y

Source DB:  PubMed          Journal:  Curr Hematol Malig Rep        ISSN： 1558-8211            Impact factor:   3.952


  34 in total

1.  Randomized phase III study of pegylated liposomal doxorubicin plus bortezomib compared with bortezomib alone in relapsed or refractory multiple myeloma: combination therapy improves time to progression.

Authors:  Robert Z Orlowski; Arnon Nagler; Pieter Sonneveld; Joan Bladé; Roman Hajek; Andrew Spencer; Jesús San Miguel; Tadeusz Robak; Anna Dmoszynska; Noemi Horvath; Ivan Spicka; Heather J Sutherland; Alexander N Suvorov; Sen H Zhuang; Trilok Parekh; Liang Xiu; Zhilong Yuan; Wayne Rackoff; Jean-Luc Harousseau
Journal:  J Clin Oncol       Date:  2007-08-06       Impact factor: 44.544

Review 2.  Mechanism of action of thalidomide and 3-aminothalidomide in multiple myeloma.

Authors:  R J D'Amato; S Lentzsch; K C Anderson; M S Rogers
Journal:  Semin Oncol       Date:  2001-12       Impact factor: 4.929

3.  Cancer statistics, 2010.

Authors:  Ahmedin Jemal; Rebecca Siegel; Jiaquan Xu; Elizabeth Ward
Journal:  CA Cancer J Clin       Date:  2010-07-07       Impact factor: 508.702

4.  Immunomodulatory drug CC-4047 is a cell-type and stimulus-selective transcriptional inhibitor of cyclooxygenase 2.

Authors:  Gregory D Ferguson; Kristen Jensen-Pergakes; Candice Wilkey; Urvi Jhaveri; Normand Richard; Dominique Verhelle; Laure Moutouh De Parseval; Laura G Corral; Weilin Xie; Christopher L Morris; Helen Brady; Kyle Chan
Journal:  J Clin Immunol       Date:  2007-02-17       Impact factor: 8.317

5.  Phase I study of an immunomodulatory thalidomide analog, CC-4047, in relapsed or refractory multiple myeloma.

Authors:  S A Schey; P Fields; J B Bartlett; I A Clarke; G Ashan; R D Knight; M Streetly; A G Dalgleish
Journal:  J Clin Oncol       Date:  2004-07-12       Impact factor: 44.544

6.  Pomalidomide and lenalidomide induce p21 WAF-1 expression in both lymphoma and multiple myeloma through a LSD1-mediated epigenetic mechanism.

Authors:  Laure Escoubet-Lozach; I-Lin Lin; Kristen Jensen-Pergakes; Helen A Brady; Anita K Gandhi; Peter H Schafer; George W Muller; Peter J Worland; Kyle W H Chan; Dominique Verhelle
Journal:  Cancer Res       Date:  2009-09-08       Impact factor: 12.701

7.  Bortezomib in combination with intermediate-dose dexamethasone and continuous low-dose oral cyclophosphamide for relapsed multiple myeloma.

Authors:  Martin Kropff; Guido Bisping; Elke Schuck; Peter Liebisch; Nicola Lang; Markus Hentrich; Tobias Dechow; Nicolaus Kröger; Hans Salwender; Bernd Metzner; Orhan Sezer; Monika Engelhardt; Hans-Heinrich Wolf; Hermann Einsele; Sarah Volpert; Achim Heinecke; Wolfgang E Berdel; Joachim Kienast
Journal:  Br J Haematol       Date:  2007-08       Impact factor: 6.998

8.  Thalidomide is an inhibitor of angiogenesis.

Authors:  R J D'Amato; M S Loughnan; E Flynn; J Folkman
Journal:  Proc Natl Acad Sci U S A       Date:  1994-04-26       Impact factor: 11.205

9.  Alternate day pomalidomide retains anti-myeloma effect with reduced adverse events and evidence of in vivo immunomodulation.

Authors:  Matthew J Streetly; Kylie Gyertson; Yvonne Daniel; Jerome B Zeldis; Majid Kazmi; Stephen A Schey
Journal:  Br J Haematol       Date:  2008-04       Impact factor: 6.998

10.  Thalidomide costimulates primary human T lymphocytes, preferentially inducing proliferation, cytokine production, and cytotoxic responses in the CD8+ subset.

Authors:  P A Haslett; L G Corral; M Albert; G Kaplan
Journal:  J Exp Med       Date:  1998-06-01       Impact factor: 14.307
View more
  6 in total

1.  Rhabdomyolysis in a multiple myeloma patient secondary to concurrent treatment with lenalidomide and pravastatin and to lenalidomide alone.

Authors:  Jaime L Shahan; Lori D Panu; Gerhard C Hildebrandt
Journal:  Int J Hematol       Date:  2012-11-28       Impact factor: 2.490

2.  The immune microenvironment of myeloma.

Authors:  Kimberly Noonan; Ivan Borrello
Journal:  Cancer Microenviron       Date:  2011-08-25

3.  Thalidomide and its analogues: A review of the potential for immunomodulation of fibrosis diseases and opthalmopathy.

Authors:  Ting Liu; Feng Guo; Xiaomin Zhu; Xiangge He; Lin Xie
Journal:  Exp Ther Med       Date:  2017-09-27       Impact factor: 2.447

Review 4.  Pomalidomide: first global approval.

Authors:  Shelley Elkinson; Paul L McCormack
Journal:  Drugs       Date:  2013-05       Impact factor: 9.546

5.  A novel phthalimide derivative, TC11, has preclinical effects on high-risk myeloma cells and osteoclasts.

Authors:  Maiko Matsushita; Yoshie Ozaki; Yuka Hasegawa; Fukiko Terada; Noriko Tabata; Hirokazu Shiheido; Hiroshi Yanagawa; Tsukasa Oikawa; Koichi Matsuo; Wenlin Du; Taketo Yamada; Masashi Hozumi; Daiju Ichikawa; Yutaka Hattori
Journal:  PLoS One       Date:  2015-01-24       Impact factor: 3.240

6.  Identification of lenalidomide resistance pathways in myeloma and targeted resensitization using cereblon replacement, inhibition of STAT3 or targeting of IRF4.

Authors:  Yuan Xiao Zhu; Chang-Xin Shi; Laura A Bruins; Xuewei Wang; Daniel L Riggs; Brooke Porter; Jonathan M Ahmann; Cecilia Bonolo de Campos; Esteban Braggio; P Leif Bergsagel; A Keith Stewart
Journal:  Blood Cancer J       Date:  2019-02-11       Impact factor: 11.037
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.